CENTOGENE is a worldwide leader in the field of genetic diagnostics for rare hereditary diseases – with the largest test portfolio worldwide. Testing samples from over 110 different countries allows CENTOGENE a unique insight into the epidemiological basis of hereditary disorders, which is crucial for interpreting results and transform it into medical reports.
The company firmly focuses on offering quality molecular genetic diagnostics, underlined by its multiple international accreditations (CAP, CLIA, ISO). Our in-depth medical expertise is supported by the application of cutting-edge technologies, including next generation sequencing, whole genome sequencing (CentoGenome®), whole exome sequencing (CentoXome®) and innovative biomarkers for selected diseases. CENTOGENE has developed a comprehensive mutation database (CentoMD®) that is pivotal to offering high-quality diagnostic reporting and medical interpretation; thoroughly interpreting each patient’s sequence data.
In addition to diagnostic services for individual patients, CENTOGENE is also a pivotal partner for numerous high-profile industrial companies worldwide.